No Data
No Data
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Business And Shares Still Trailing The Industry
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment opportunity when you consider close to half the companies
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan
Shenzhen Neptunus Bioengineering (SHE:000078), through its subsidiary Shandong Neptune Galaxy Pharmaceutical, will build the first phase of a smart logistics park for 298 million yuan, according to th
Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term Shenzhen Neptunus Bioengin
Haiwang Biotech (000078.SZ): It has now built a diversified, multi-level pharmaceutical product structure
Gelonghui, Feb. 5 | Haiwang Biotech (000078.SZ) said on the investor interactive platform that the company's pharmaceutical industry sector is mainly engaged in drug R&D, production and sales, with subsidiaries Haiwangfu Pharmaceutical, Jinxiang Traditional Chinese Medicine and Haiwang Zhongxin Pharmaceutical as the main platforms. The company has now built a diversified and multi-level pharmaceutical product structure. Haiwang Pharmaceutical's main business is R&D, production and sales of large infusion products, Western medicine preparations, etc.; Jinxiang Traditional Chinese Medicine is a medium-sized traditional Chinese medicine manufacturer and sales enterprise in Fujian Province, responsible for R&D, production and sales of proprietary Chinese medicines; Haiwang Zhongxin Pharmaceutical is a company integrating R&D, production and sales of pharmaceutical products
Shenzhen Neptunus Bioengineering (SZSE:000078) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Why Investors Shouldn't Be Surprised By Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Low P/S
With a price-to-sales (or "P/S") ratio of 0.2x Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) may be sending very bullish signals at the moment, given that almost half of all the Healthcare
No Data